← Research library / Immune
Thymosin alpha-1 is a real hormone fragment, not a designer molecule. The thymus produces it, it plays a role in T-cell maturation, and production declines with age alongside thymic involution. That gives it a more coherent biological story than most compounds here.
The strongest evidence is in chronic hepatitis B and C, where it has been used as an adjunct to interferon therapy, and that work supported approvals across Europe, Asia and South America. There is also a body of work in sepsis and immune reconstitution.
COVID-19 produced a burst of new research, some of it suggesting benefit in severe cases with lymphopenia. Results were mixed and the studies were largely observational or small.
The honest answer is commercial rather than scientific. It holds orphan designation but the sponsor never took it through to a US approval, and the compounding pathway is separately constrained. Absence of US approval here does not mean the evidence is absent, which is unusual in this category and worth stating plainly.
Immune modulation cuts both ways. Anyone with an autoimmune condition, or on immunosuppressive therapy including after transplant, should treat this as a conversation with a specialist rather than a wellness decision.
Full library · Safety and sourcing · Reconstitution calculator · The 2026 regulatory picture
Regulatory status current as of the page date. This area is changing quickly and this page is reviewed monthly.